Tallet A, Lambaudie E, Cohen M, Minsat M, Bannier M, Resbeut M, Houvenaeghel G. Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy. World J Clin Oncol 2016; 7(2): 243-252 [PMID: 27081647 DOI: 10.5306/wjco.v7.i2.243]
Corresponding Author of This Article
Gilles Houvenaeghel, MD, Departement of Surgery, Institut Paoli Calmettes and CRCM, 232 Bd de Sainte Marguerite, 13009 Marseille, France. houvenaeghelg@ipc.unicancer.fr
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Apr 10, 2016; 7(2): 243-252 Published online Apr 10, 2016. doi: 10.5306/wjco.v7.i2.243
Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy
Agnès Tallet, Eric Lambaudie, Monique Cohen, Mathieu Minsat, Marie Bannier, Michel Resbeut, Gilles Houvenaeghel
Agnès Tallet, Mathieu Minsat, Michel Resbeut, Departement of Radiotherapy, Institut Paoli Calmettes and CRCM, 13009 Marseille, France
Eric Lambaudie, Monique Cohen, Marie Bannier, Gilles Houvenaeghel, Departement of Surgery, Institut Paoli Calmettes and CRCM, 13009 Marseille, France
Eric Lambaudie, Gilles Houvenaeghel, Aix Marseille Université, Jardin du Pharo, 13284 Marseille, France
Author contributions: Tallet A, Lambaudie E and Houvenaeghel G performed the majority of the writing and prepared tables; others have contributed to the writing of manuscript.
Conflict-of-interest statement: There is no conflict of interest associated with any of senior author, coauthors, contributed their efforts in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Gilles Houvenaeghel, MD, Departement of Surgery, Institut Paoli Calmettes and CRCM, 232 Bd de Sainte Marguerite, 13009 Marseille, France. houvenaeghelg@ipc.unicancer.fr
Telephone: +33-04-91223532 Fax: +33-04-91223613
Received: June 19, 2015 Peer-review started: June 27, 2015 First decision: July 31, 2015 Revised: February 25, 2016 Accepted: March 9, 2016 Article in press: March 14, 2016 Published online: April 10, 2016 Processing time: 292 Days and 16.3 Hours
Abstract
The advent of sentinel lymph-node technique has led to a shift in lymph-node staging, due to the emergence of new entities namely micrometastases (pN1mi) and isolated tumor cells [pN0(i+)]. The prognostic significance of this low positivity in axillary lymph nodes is currently debated, as is, therefore its management. This article provides updates evidence-based medicine data to take into account for treatment decision-making in this setting, discussing the locoregional treatment in pN0(i+) and pN1mi patients (completion axillary dissection, axillary irradiation with or without regional nodes irradiation, or observation), according to systemic treatment, with the goal to help physicians in their daily practice.
Core tip: Sentinel lymph-node biopsy has led to a shift in lymph-node staging, due to the emergence of new entities namely micro-metastases and isolated tumor cells. The prognostic significance of this low positivity in axillary lymph nodes is currently debated, as is, therefore its management. This review provides updates evidence-based medicine data to take into account for treatment decision-making in this setting, discussing several loco-regional therapeutic strategies based on recent clinical trials results, particularly completion axillary dissection, axillary irradiation, regional nodes irradiation, with according to systemic treatment, with the goal to help physicians in daily practice.
